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Abstract
Objective: hepatitis c virus (hcV) infection is a major cause of liver disease. since symptoms of chronic liver disease 
usually appear only late in the course of the disease, infected individuals may remain undiagnosed until advanced disease 
has developed. We aimed to investigate which screening strategies would be most effective to detect individuals unaware 
of their infection.
Methods: We developed a mathematical model for hcV disease progression and compared the current practice of hcV 
testing in switzerland with the following screening strategies: intensive screening of active injection drug users (iDU), 
screening of former iDU, screening of individuals originating from countries with high hcV prevalence, screening of 
individuals born 1951–1985 (birth-cohort) and universal screening. all screening interventions were considered in 
addition to a baseline scenario that reflected the current practice of hcV testing.
Results: Within the first 4 years (2018–2021), every year, on average 650 cases were diagnosed in the baseline scenario, 
660 with intensified iDU screening, 760 with former iDU screening, 830 with origin-based screening, 1420 with birth-
cohort screening and 1940 with universal screening. no difference in liver-related mortality and incidence of end-stage 
liver disease between the screening scenarios was observed.
Conclusion: Our results suggest that only large-scale screening of the general population could substantially accelerate 
the rate of hcV diagnosis and treatment in switzerland and other countries with similar epidemics. however, this implies 
screening of a large population with low prevalence, and may trigger considerable numbers of false-positive and borderline 
test results.
Keywords: hepatitis c infection, mathematical model, screening
Introduction
hepatitis c virus (hcV) infection is a major cause of liver disease 
and liver-related mortality [1–3]. hcV prevalence of up to 15% 
has been reported in some countries; it may also be up to 1% 
in several high-income countries [1,4]. about 40,000 people 
(0.5% of the general population) were estimated to be chroni-
cally infected with hcV in switzerland in 2016 [5].
as in many high-income countries, the majority of reported cases 
in switzerland is concentrated among injection drug users (iDU) 
[5–8]. after 2000, the number of new infections among iDU has 
decreased following the intensified implementation of harm-
reduction measures [5,7]. sexual transmission of hcV is possible 
but rare in the general population [9,10]. however, increased 
hcV incidence has been reported among hiV-positive men who 
have sex with men (MsM) [5,11]. Most health care-associated 
hcV transmissions occurred before blood products were system-
atically screened for hcV and before adequate methods were 
introduced to prevent transmission by invasive medical procedures 
[5,12]. increased hcV prevalence is also found in other groups 
such as migrants originating from high-prevalence countries 
[5,12,13]. in 2014, direct-acting antivirals (Daa) with a cure 
rate of >90% became available and are now the gold standard 
of hcV treatment [12,14]. since October 2017, Daa treatment 
has been reimbursed for all hcV-infected patients in switzerland, 
regardless of liver disease stage [6,15].
infected persons may be unaware of their infection for decades 
[16]: liver-related complications develop slowly and may not 
appear for at least 10 years after infection [16,17]. consequently, 
case detection based on symptoms and self-reported risk factors 
may be insufficient. some countries have implemented policies 
of wider screening: for example, in France it is now recommended 
that every adult is tested at least once during their lifetime [18]. 
in switzerland, like in many other countries, blood, organ and 
cell donations are systematically screened for hcV, and hcV 
testing is recommended for persons with clinical symptoms of 
hepatitis or medical, demographic, occupational or other risk 
factors associated with hcV [12]. however, there is no national 
policy or action plan to screen wider population groups [6,12]. 
Broader screening may accelerate the identification of hcV-infected 
individuals and, together with Daa treatment, reduce the long-
term burden of the disease. We therefore developed a mathematical 
model to explore the impact of different screening strategies on 
hcV diagnosis and the number of cases of decompensated cir-
rhosis (Dc), hepatocellular carcinoma (hcc) and liver-related 
deaths in switzerland.
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Methods
Model structure
We developed a mathematical model using the r package gems 
[19] to quantify hcV disease progression. in gems, disease pro-
gression is represented by a directed acyclic graph of health 
states. in each state, transition times to all possible destination 
states are sampled. The minimum of these times determines when 
and to which state the patient will move. The process is repeated 
until the patient reaches a terminal state. We adapted the model 
structure of Zahnd et al. [20] and simulated cohorts of patients 
from the time of infection until death. The patients progress 
along two dimensions, representing the progression of liver disease 
and the course of hcV infection including the cascade of care 
(Figure 1). The stage of liver disease is defined according to the 
MeTaVir scoring system (F0–F4) followed by Dc, hcc and liver 
transplantation (lT). The progression of hcV infection and care 
is divided into acute infection, chronic undiagnosed infection, 
chronic diagnosed infection, first treatment, second treatment 
and undetectable hcV. Death was represented using four separate 
states depending on the cause: liver-related, hiV-related, iDU-
related and other causes. The patients who spontaneously clear 
hcV or achieve sustained virological response (sVr) after treat-
ment move to the states with undetectable hcV viral load. We 
assumed that spontaneous clearance or achievement of  sVr 
decreased the fibrosis progression rates by 90% [20]. Fibrosis 
regression after sVr was not considered in the model. For sim-
plicity, we did not include a separate state for failing treatment. 
We only considered treatment with Daa and excluded patients 
treated successfully with pre-Daa treatment [21–24]. We assumed 
that patients could be treated with Daa in stage F2 or above 
between 2014 and 2017, and regardless of fibrosis stage from 
2018 onwards [6]. Patients who were diagnosed before 2014 
started treatment after a random delay between 0 and 15 years 
after becoming eligible for treatment. Patients diagnosed from 
2014 onwards were treated on average 6 months after meeting 
the eligibility criteria [25]. Probability of achieving sVr was 98% 
regardless of genotype or other characteristics [14]. at the begin-
ning of the simulation, patients were assigned the following 
characteristics: birth year, age at infection, sex, region of origin, 
hiV co-infection and its duration, alcohol consumption, high-risk 
sexual MsM behaviour, and the duration of injecting drug use 
(supplementary Tables 1–2).
Data sources
We obtained the distribution of baseline characteristics among 
the currently diagnosed patients from the swiss Federal Office 
of Public health (FOPh) notification database (supplementary 
Figure 1). This database contains all notified cases of hcV in 
switzerland since 1988. We used the data on age, sex, region 
of geographic origin and the expected route of transmission at 
the year of notification. We assumed that half of the patients in 
the database who were treated in the pre-Daa era achieved sVr 
and were thus excluded from our analyses [21,23]. The FOPh 
database does not include information on alcohol consumption 
or hiV co-infection. These characteristics were estimated from 
the swiss hepatitis c cohort study (sccs) [26] by matching the 
patients in the FOPh database with the patients in the sccs 
based on the year of infection and common baseline character-
istics. When there were no patients in the sccs for a particular 
combination of infection year and baseline characteristics, we 
assumed that the proportions of individuals with severe, mod-
erate and abstinent alcohol consumption were equal and that 
individuals with high-risk MsM behaviour were hiV co-infected.
Figure 1. structure of the simulation model. individuals can progress vertically based on liver disease and horizontally through the hepatitis c virus (hcV) infection and cascade of 
care. First and second treatments contain the treatment episode itself and, in case of treatment failure, the time after ending therapy. Death can occur at any state (not 
shown in the graph for simplicity). F0–F4: stages of fibrosis according to the MeTaVir scoring system; Dc: decompensated cirrhosis; hcc: hepatocellular carcinoma;  
lT: liver transplantation
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Years of starting and ending active drug use, containing also 
substitution therapy, were assigned to all simulated iDU. similarly, 
we assigned each hiV co-infected patient a year of hiV infection.
We reviewed the literature to parameterise the model. We chose 
parameter values that would best represent the situation in swit-
zerland, consulting experts if necessary. We parameterised fibrosis 
progression from F0 to F4 assuming stage- and age-dependent 
rates as proposed by razavi et al. [27]. and harris et al. [28]. 
(supplementary Tables 3–5). Parameters for liver-related mortality 
and the cascade of hcV infection and care can be found in sup-
plementary Tables 6–7.
Fitting the model to the data of the local hcV registry
We first simulated generic cohorts of patients for all combinations 
of baseline characteristics. Then, we assigned each simulated 
patient a weight corresponding to the representativeness in the 
true hcV-infected population in switzerland. The weights were 
based on the analyses of the FOPh and sccs databases for the 
population diagnosed by 2015, and on our assumptions concern-
ing the population that had not yet been diagnosed. We first 
determined the weights for the simulated individuals corresponding 
to the diagnosed patients in the FOPh data and used the model 
to back-calculate the year of infection in this population (sup-
plementary Figures 2–3). We assumed that the number of annual 
new infections among individuals of swiss origin would follow 
approximately the distribution of infection years among people 
already diagnosed, with the probability of being diagnosed by 
year 2015 slightly decreasing over time. We then modified the 
number of new infections each year to account for the expected 
peak in new infections around the early 1990s, during the time 
of the major changes in drug policy [7,29,30]. For the patients 
of foreign origin, we assumed a decline in new infections over 
the years, influenced by differences in migration patterns and 
the hcV prevalence in the respective countries of origin [5,6,13]. 
The size of the viremic population living in switzerland was 
assumed to be approximately 40,000 in 2016 [5].
We applied the distribution of baseline characteristics of the 
diagnosed patients infected in a particular year to the undiagnosed 
individuals infected in the same year. We assumed the number 
of annual new infections in the future would remain at the level 
of 2015 (supplementary Table 8).
screening strategies
We modelled a baseline scenario and five screening interventions 
from the year 2018 onwards. all five interventions were built on 
top of the baseline scenario. in the baseline scenario, hcV testing 
continued in the future as in 2017 (Table 1). With a scenario 
of intensified iDU screening, the rate of testing active iDU was 
increased from 0.5 to 1.0 per person-year. in the origin-based 
scenario, people from southern europe, africa and asia were 
tested with a rate of 0.5 per person-year. in the birth-cohort 
screening scenario, the rate 0.5 per person-year was applied to 
individuals born between 1951 and 1985 [31], and with universal 
screening, to all individuals. in all scenarios, the patients had an 
hcV antibody test, followed by a confirmatory nucleic acid test 
in case of a positive antibody test result.
sensitivity analyses
We conducted six sensitivity analyses (s1–s6) to address the 
uncertainty around parameters and assumptions (supplementary 
Table 9). First, we conducted a sensitivity analysis around the 
size of the viremic population in 2016, assuming it was either 
40% higher (sensitivity analysis s1) or 10% lower (s2) than in 
the main analysis. second, we assumed that the proportion of 
Table 1. rate of hcV testing based on different risk factors without 
screening interventions. The rates are based on assumptions 
and discussion with experts 
Risk indicator When applied Value (rate per 
person-year)
symptoms Fibrosis F3 or higher F3: 1
F4: 2
Dc or hcc: 5
Background 
testinga
regardless of fibrosis stage 0.01
Drug use active iDU 0.5
hiV infection, 
high-risk MsM
high-risk MsM 1year after 
hiV infection
1
high-risk MsM 
(hiV negative)
high-risk MsM until 1 year 
after hiV infection
0.5
hiV infection 
(not MsM)
Other hiV infected patients 
since the time of infection
0.2
Dc: decompensated cirrhosis; F3, F4: fibrosis stage according to 
MeTaVir score; hcc: hepatocellular carcinoma; iDU: injection drug 
user; MsM: men having sex with men.
a Background testing includes tests that are not triggered by any risk 
factor or symptom, such as suspicion based on high liver values 
observed in routine blood test, or hcV tests among blood donors.
individuals with high-risk behaviour was either higher (s3) or 
lower (s4) among the undiagnosed than the diagnosed popula-
tion infected in the same year. Third, we reduced the rate of hcV 
diagnoses among iDU before 2018 (s5). Finally, we investigated 
the effect of fibrosis progression rates by using an alternative 
parameterisation of the liver disease progression (s6), assuming 
a constant rate of fibrosis progression across all stages [2].
Results
screening scenarios
in the baseline scenario, on average 650 hcV-infected individuals 
were diagnosed annually during the first 4 years (2018–2021), 
and this number decreased to about 300 individuals by 2030 
(Figure 2). intensified screening among active iDU (660 diagnoses 
annually during years 2018–2021, 1% increase from baseline) 
and screening former iDU (760 diagnoses annually during years 
2018–2021, 17% increase) led to similar results. screening based 
on geographic origin slightly increased the number of diagnoses 
during the first 4 years, with 830 (28% increase from baseline) 
annual diagnoses. in the following years, the number remained 
stable in all of these four scenarios, at about 500 per year. With 
birth-cohort and universal screening, the number of new diagno-
ses was substantially higher in the year 2018 than in the other 
scenarios. Birth-cohort and universal screening strategies could 
identify on average 1420 (118% increase from baseline) and 1940 
(198% increase from baseline) patients per year in 2018–2021, 
respectively. From 2022, the number started to decrease, reach-
ing 140 (birth-cohort) and 100 (universal) diagnoses in 2029.
On average, 4720 patients can be expected to achieve sVr annu-
ally within the years 2018–2021 in the baseline scenario. The 
corresponding numbers (with increase compared with baseline) 
were 4760 (1%) for the intensified screening of active iDU, 5020 
(6%) for the screening of former iDU, 4960 (5%) for the origin-
based screening, 6000 (27%) for birth-cohort screening and 
6600 (40%) for universal screening. From 2022 onwards the 
average number of patients achieving sVr ranged from 1200 to 
2400 per year across the strategies.
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Figure 2. number of annual new hepatitis c virus (hcV) diagnoses in switzerland: a comparison between different screening scenarios (2018–2029). iDU: injecting drug user
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Figure 3. number of viremic individuals, diagnosed and undiagnosed: a comparison between different screening scenarios (2018-2029). iDU: injecting drug user
The size of the viremic population is expected to remain above 
5800 over the next decade in the baseline scenario and with 
intensified screening of current iDU, despite the initial decrease 
(Figure 3). screening based on origin or screening former iDU 
decreased the size of the viremic population slightly, compared 
with the baseline scenario, leading to about 5000 (14% decrease 
from baseline) and 4000 (31% decrease from baseline) viremic 
individuals in 2029, respectively. Birth-cohort and universal screen-
ing led to a considerable decrease in the number of viremic indi-
viduals, with about 1900 (67% decrease from baseline; birth-cohort 
screening) and 600 (90% decrease from baseline; universal 
screening) viremic people living in switzerland in 2029.
The model showed no major differences in liver-related morbidity 
and mortality between the scenarios during the years 2018–2029 
(supplementary Table 10). The total number of cases of Dc, hcc 
and liver-related deaths within the period 2018–2029 ranged 
from 960 to 1430, 200 to 350 and 1700 to 2000, respectively, 
across the screening strategies (Figure 4). The differences among 
the strategies are likely due to stochastic variability.
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sensitivity analyses
The annual number of new infections stayed around 1000 until 
the early 1980s in the main analysis, and started to increase 
thereafter, peaking at 1900 during the years 1995–1999 and 
followed by a decrease (Figure 5). a major difference was seen 
in the sensitivity analysis s1 with a larger viremic population: 
between 1971 and 1990, the number of new infections was 
twice as high as in the main analysis. There were no major dif-
ferences between the main analysis and the analyses s2 and s5 
in terms of newly infected individuals. however, for the analysis 
in which the diagnosis rate among iDU was lower (s5), the peak 
of new infections occurred 5–10 years earlier. The numbers of 
new infections in the analyses s3 and s4 were, by definition, 
the same as in the main analysis. in the analysis with constant 
fibrosis progression (s6) (supplementary Table 11), the number 
of liver-related deaths and cases of Dc and hcc were about half 
of those in the main analysis (supplementary Table 10).
regarding future projections, universal and birth-cohort screen-
ing yielded the same results in the main and sensitivity analyses 
(supplementary Figure 4). The only major difference was in the 
analysis with more high-risk individuals (s3), where the effect 
of screening former iDU in 2018 was similar to birth-cohort 
screening.
Discussion
Principal findings
We forecasted the impact of several hcV testing strategies on the 
number of new hcV diagnoses, the size of the viremic population 
and the magnitude of liver-related complications and deaths in 
switzerland between 2018 and 2029 using a disease progression 
model. Birth-cohort and universal screening seemed to be the 
most effective strategies for identifying the undiagnosed hcV-
infected individuals within the next 4 years and for reducing the 
size of the viremic population. however, we could not show a 
clear difference in liver complications or mortality between the 
screening strategies, most probably due to stochastic variability 
in the model.
Figure 4. number of liver-related deaths among hepatitis c virus (hcV)-infected individuals in switzerland: a comparison between different screening strategies (2018-2029)
Figure 5. number of new hepatitis c virus (hcV) infections per year in switzerland in the past: a comparison of the main analysis and the sensitivity analyses. iDU, injecting drug 
user; s1: more undiagnosed people in 2016, s2: less undiagnosed people in 2016, s5: low iDU diagnosis rate; s6: constant progression rate
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implementing broad strategies such as birth-cohort or univer-
sal screening requires testing a large low-prevalence popula-
tion, indicating a high cost per diagnosis. The feasibility of such 
screening strategies should be studied from the acceptability and 
cost-effectiveness perspective. Universal screening of 8 million 
residents over the next 12 years to identify about 10,000 infec-
tions would add a considerable burden to switzerland’s healthcare 
budget. The indirect costs related to false-positive and borderline 
test results should also be added [32–35]. Therefore, although 
universal screening could reduce the hcV viremic population by 
2030, implementing such strategy would be challenging. screening 
only the 3.6 million individuals born between 1951 and 1985 
could halve the number of people tested [36]. studies from the 
Us have suggested that one-time birth-cohort screening could 
be cost-effective [37–40]. however, the eldest individuals, who 
have the highest rate of disease progression and may otherwise 
be more difficult to detect on time, would not benefit from 
birth-cohort screening [2,13].
screening former iDU may also help to detect a substantial number 
of cases. however, the effectiveness of this strategy depends on 
the assumptions of the model. if we assumed that iDU were fre-
quently tested in the past, screening former iDU provided almost 
no benefit. in contrast, assuming a considerably lower testing rate 
for active iDU in the past, screening of former iDU was almost as 
effective as birth-cohort screening, mainly because former iDU 
remained untested in the years of active drug use. identifying 
former iDU can, however, be challenging. Despite the pragmatic, 
harm reduction oriented drug policy of switzerland, persons who 
only occasionally injected drugs in the past will unlikely iden-
tify themselves as having been at risk for hcV infection [41]. 
intensifying the screening of current iDU was, as expected, not 
very effective: we assumed a relatively high testing rate among 
iDU in our baseline scenario [5–7,12], although shortcomings 
of testing in this population are observed [7,42,43].
liver-related mortality and the incidence of liver complications 
did not essentially differ between the scenarios. The observed 
differences were not systematic and thus mainly due to random 
variability. Furthermore, we only modelled the next 12 years. 
Therefore, we cannot exclude the possibility that screening would 
reduce mortality in the longer term. Background mortality also 
is a competing risk factor: patients who most benefit from addi-
tional screening tend to be older, and mortality is increased in 
persons with iDU [44].
Our results show that the number of viremic individuals will likely 
decrease over time in all screening strategies: in 2030, we expect 
to have no more than 5000 viremic individuals in switzerland, 
with large-scale screening strategies even considerably less. 
This represents a multiple-fold decrease from the current level. 
Viremic individuals may transmit the virus onwards: however, 
the risk of transmission also depends on the risk behaviour. The 
analysed screening strategies target mainly populations outside 
the groups with most ongoing transmission such as active iDU 
and hiV-infected MsM. it is therefore unlikely that screening 
would substantially affect the transmission dynamics. neverthe-
less, the impact of screening on the number of new infections 
needs verification with a transmission model before conclusions 
can be made.
strengths and limitations
Our study is among the first to compare the effect of different 
hcV testing strategies on the epidemiological determinants of 
hcV infection in a nationwide setting. as in many other high-
income countries, the epidemic in switzerland is concentrated 
among injecting drug users and hiV-infected MsM, but other 
population groups may have also been exposed through, for 
example, unsafe medical procedures or one-time use of intravenous 
drugs. The results should be therefore applicable in a wide range 
of settings. several mathematical models have estimated the 
progression, transmission and epidemiological and financial burden 
of hcV infection [45–48]. These models were usually limited to 
a specific subpopulation or tailored to a particular research ques-
tion, or they did not take into account the individual-level risk 
factors. Our study benefited also from a systematic collection of 
hcV notification data since 1988.
Our study has several limitations. First, transmission is not included 
in our model. The absolute numbers should be interpreted with 
caution, as these are sensitive to several external factors, such 
as ongoing transmission and migration. Moreover, the number 
of new infections is a fixed input and the model thus does not 
take into account the impact of future interventions that target 
transmission. second, to avoid complexity, we did not take into 
account the false-negative test results and retesting [49]. False-
negative antibody tests can occur in very early infection and in 
immunosuppressed patients. however, as the majority of the hcV-
infected population is not immunosuppressed [26], false-negative 
antibody tests are likely rare and should not essentially impact the 
results. Third, there are some limitations and uncertainty around 
the model parameters, including fibrosis progression rates and 
the assumptions regarding the currently undiagnosed population. 
The true hcV prevalence and the baseline characteristics of the 
undiagnosed individuals are difficult to estimate and cannot be 
determined without the collection of new primary data. Fourth, 
we did not model treatment with interferon and ribavirin, and 
the data for Daa treatment are limited to the period from 2014 
when Daa became widely available. as the aim of the study was 
to compare screening strategies for identifying the undiagnosed 
infected individuals, the restriction to Daa treatment should not 
essentially influence the results. exclusion of the pre-Daa therapy, 
however, complicates the validation of the model against past 
observations. Finally, the number of reported hcV-infected patients 
may be subject to various types of bias, such as possible inac-
curate estimates of the number of hcV-infected persons who 
have emigrated or died.
Conclusion
among the testing scenarios that we studied, only large-scale 
screening strategies could accelerate hcV detection. screening 
people with a history of injecting drug use could also be effective, 
but the benefit of this strategy depends largely on assumptions 
of the characteristics of the undiagnosed population that cannot 
currently be verified. We could not show an essential difference 
in mortality and the incidence of Dc or hcc across the screening 
scenarios. Our results underline the need to explore the feasibility 
of different hcV testing strategies in low-prevalence settings, 
and to evaluate the potential financial burden of implementing 
a large-scale screening strategy.
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Supplementary Table 1. Baseline characteristics included in the 
model
Baseline 
characteristics
Value Source of 
distribution
alcohol 
consumption
severe (on average >40 g/day), 
moderate (on average 20–40 g 
per day), abstinent
sccs data
sex Male, Female FOPh data
hiV no, Yes sccs data
high-risk sexual 
MsM behaviour
no, Yes FOPh data
iDU no, Yes FOPh data
geographic origin switzerland, Western europe, 
eastern europe, Others
FOPh data
age (years) <21, 21–31, 32–41, 42–51, 
52–61, 62–71, 72–81, >81
FOPh data
Year of birth 1937–1947, 1948–1957, 
1958–1967, 1968–1977, 
1978–1987, 1988–1997, 
1998–2006, 2007–2016
FOPh data
FOPh: Federal Office of Public health; iDU: injecting drug user; MsM: 
men who have sex with men; sccs: swiss hepatitis c cohort study. 
Supplementary Table 2. Distribution of fibrosis stages at the begin-
ning of the simulation [1]
METAVIR stage at HCV infection Probability (%)
F0 85.90
F1 15.09
F2 1.84
F3 0.24
F4 1.50
Supplementary Table 3. Disease progression rates between MeTaVir stages F0 and F4 according to sex and current age [2,3]a
Age (years) 10–19 20–29 30–39 40–49 50–59 60–69 70–79 80+
Fibrosis progression rate per 100 person-years: Male
 F0 → F1 4.5 3.7 2.7 9.9 12.1 13.8 15.5 12.7
 F1 → F2 3.3 2.7 1.9 7.2 8.8 10.0 11.2 13.0
 F2 → F3 4.7 3.8 2.8 10.2 12.4 14.1 15.9 13.0
 F3 → F4 0.6 1.8 4.0 6.3 3.4 7.0 13.6 13.6
Fibrosis progression rate per 100 person-years: Female
 F0 → F1 3.8 3.1 2.2 8.2 10.2 11.5 12.9 10.6
 F1 → F2 2.8 2.2 1.6 6.0 7.4 8.3 9.4 7.7
 F2 → F3 3.9 3.1 2.3 8.5 10.4 11.8 13.2 10.9
 F3 → F4 0.4 1.5 3.3 5.3 2.8 5.9 11.3 11.3
a We used the fibrosis progression rates between MeTaVir stages F0 and F4 from a study conducted by razavi et al. [3] where fibrosis progression rates were 
back-calculated from data from the Us (Us surveillance, epidemiology and end results). They used the results of harris et al. [2], who used a similar 
back-calculation method for calculating the fibrosis progression rates for patients from the UK, as a guidance.
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Supplementary Table 4. Model parameters for liver disease progression from MeTaVir stage F4 onwards (rate per 100 person-years)
Liver disease progression/age (years) 0-29 30-39 40-49 50-59 60-69 70+ References
F4 → Dc 6.51 6.41 6.48 6.49 6.35 6.30 [2,4]
F4 → hcc 0.79 1.30 2.12 3.47 5.65 9.13 [2,4]
Dc → hcc 1.55 2.52 4.10 6.65 10.91 17.62 [5]
Dc → lT 3.1 3.1 3.1 3.1 3.1 3.1 [6]
hcc → lT 1.7 1.7 1.7 1.7 1.7 1.7 [7]
Dc: decompensated cirrhosis; hcc: hepatocellular carcinoma; lT: liver transplantation.
Supplementary Table 5. hazard ratio to modify the rate of liver disease progression for moderate or excessive alcohol consumption. The rates shown 
in supplementary Table 4 are multiplied by these hazard ratios, depending on the patient’s level of alcohol consumption
METAVIR stage/alcohol consumption Abstinent Moderate Severe References
F0 → F1 1 1.16 1.33 [8,9]
F1 → F2 1 1.3 2.22 [10]
F2 → F3 1 1.3 2.22 [8,11]
F3 → F4 1 1.16 4 [8,9]
Supplementary Table 6. liver-related mortality rates per 100 person-years from F4, Dc, hcc and lT
Event (state of liver disease → Death) Value References
F4 → Death 0.010 [7]
Dc → Death 0.129 [6,7,12,13]
hcc → Death 0.430 [6,7,12,13]
lT → Death (first year) 0.160 [6,7,12,13]
lT → Death (second year) 0.057 [6,7,12] 
Background mortality rates were taken from the Federal Office of statistics database.
F4: cirrhosis; Dc: decompensated cirrhosis; hcc: hepatocellular carcinoma; lT: liver transplantation.
Supplementary Table 7. Model parameters for the cascade of hcV infection and care
Event Origin state → Destination 
state
Description and parameter’s value Reference
chronic acute → chronic undiagnosed Duration of acute infection is 6 months for all patients [14]
Diagnosed Undiagnosed → Diagnosed Main text – Table 1 assumption
spontaneous 
clearance
acute, Undiagnosed, 
Diagnosed → cleared
We assumed that the probability of spontaneously clearing hcV follows a 
logistic decrease, with an overall probability of 32%
[1]
First treatment Diagnosed → First treatment Time from diagnosis to treatment by 2014 was sampled from a uniform 
distribution between 0 and 15 years
Time from diagnosis to treatment after 2014 was sampled from a uniform 
distribution between 0 and 1 year
assumption
second treatment First treatment → second 
treatment
Time from diagnosis to treatment by 2014 was sampled from a uniform 
distribution between 0 and 15 years
Time from the first treatment to the second treatment after 2014 was 
sampled from a uniform distribution between 0 and 1 year
assumption
Duration — 12 weeks regardless of the hcV genotype and liver disease stage assumption
cure with Daa Treatment → cleared 98% regardless of genotype [15,16]
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Supplementary Table 8. expected number of new hepatitis c infections 1970–2029, switzerland
Year 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982
number of new infections 222 810 851 894 807 854 807 900 821 904 773 912
Year 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995
number of new infections 908 1033 946 1120 1252 1357 1267 1471 1602 1826 1822 1944 2062
Year 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
number of new infections 1927 2084 1777 1705 1639 1695 1570 1397 1311 1263 1202 1070 1073
Year 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019–2029
number of new infections 1012 1004 953 876 704 543 221 200 200 200 200
Supplementary Table 9. Description of the sensitivity analyses. high-risk population: iDUs and high-risk sexual MsM behaviour (and low-risk popula-
tion is the remaining)
Sensitivity 
analysis
Description (Assumption)
s1 The size of viremic population in 2016 was assumed to be 40% higher than the main analysis.
s2 The size of viremic population in 2016 was assumed to be 10% lower than the main analysis.
s3 The size of the viremic population in 2016 was as in the main analysis, but the number of low-risk individuals among the undiagnosed 
individuals was decreased by 50%, and the number of high-risk individuals increased accordingly.
s4 The size of the undiagnosed low-risk population infected each year was increased to twice as the original, and the number of 
undiagnosed high-risk individuals infected in the same year was decreased to have the same total number of individuals as in the main 
analysis (the high-risk population is defined as s3).
s5 in s5, it is assumed that low diagnosis rate increased over time with the rate of 0.05/person-year until 1990, 0.1/person-year in 
1990–1995, 0.15/person-year in 1996–2000,0.25/person-year in 2001–2018 and 0.5/person-year from 2018 onwards.
s6 a constant rate of fibrosis progression according to age at infection was applied across all stages (supplementary Table 11).
iDU: injecting drug user; MsM: men who have sex with men.
Supplementary Table 10. number of liver complications in 2017–2018 for different screening strategies
Event-Year 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
Baseline
 Dc 264 231 163 124 80 73 54 46 30 25 20 25
 hcc 71 39 63 20 26 13 14 5 16 10 2 3
 Death 223 197 218 231 193 227 88 120 175 114 100 114
iDUs
 Dc 234 164 134 104 58 50 33 28 7 16 17 19
 hcc 69 18 29 20 22 9 6 5 16 10 26 2
 Death 174 153 189 153 207 223 102 126 91 113 124 148
Former iDUs
 Dc 228 158 134 103 58 49 33 36 8 17 15 15
 hcc 68 16 29 19 20 8 5 5 14 10 21 2
 Death 155 132 188 136 154 197 87 112 93 106 143 153
geographic origin
 Dc 236 188 178 117 66 44 32 18 12 21 19 22
 hcc 80 23 52 6 10 5 6 4 2 0 1 5
 Death 222 199 217 247 179 227 85 129 175 118 99 95
Birth-cohort
 Dc 265 248 161 123 75 68 51 42 28 24 19 25
 hcc 71 38 66 18 28 12 12 4 14 9 3 4
 Death 157 126 161 180 158 264 222 151 84 192 72 107
Universal
 Dc 236 142 116 79 38 11 8 7 6 6 6 10
 hcc 40 28 12 1 41 0 8 2 0 0 2 6
 Death 155 133 143 265 119 199 224 86 102 174 74 94
Dc: decompensated cirrhosis; hcc: hepatocellular carcinoma; Death: liver-related death; iDU: injecting drug user.
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Supplementary Table 11. Disease progression rates between fibrosis stages F0 and F4 according to age at infection: parameters for analysis with 
constant fibrosis progression (sensitivity analysis s6) [8]
Age at infection(years) Value Description
<20 0.091
21–30 0.105 These values are applied to all steps from F0 to F4.
31–40 0.138
41–50 0.200
>51 0.333
Supplementary Figure 1.  Distribution of sex, year of birth, exposure through injection drug use and geographic origin in the Federal Office of Public health database (from 1988 
to 2015, and excluding the patients who had missing information on the presented characteristics). iDU: injecting drug user; MsM: men who have sex 
with men 
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Supplementary Figure 2.  number of new infections per year in the past: comparison between persons of swiss and foreign origin
Supplementary Figure 3. coefficients for new infection in the swiss origin and foreign origin populations. each simulated patient is assigned a weight showing how often a similar 
patient appeared in the real data. as the real data do not include the undetected hcV-infected population, we defined an amplifying coefficient for swiss origin and 
foreign origin population per year. This can give us a rough assumption about the true hcV incidence. The coefficients are chosen to emphasise the hcV incidence mainly 
among the persons of foreign origin in the early 1970s, and among the persons of swiss origin in the late 1980s and early 1990s during the drug policy changes in 
switzerland
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Supplementary Figure 4. sensitivity analysis around the size of viremic population (s1 and s2), proportion of the high-risk population (s3 and s4), past rate of diagnosis among 
iDU (s5), and fibrosis progression rate (s6). iDU: injecting drug user.
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